



(51) International Patent Classification:

C12N 15/113 (2010.01) C12N 9/10 (2006.01)
C07K 19/00 (2006.01)

(21) International Application Number:

PCT/US2024/029529

(22) International Filing Date:

15 May 2024 (15.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/502,325	15 May 2023 (15.05.2023)	US
63/516,096	27 July 2023 (27.07.2023)	US
63/581,236	07 September 2023 (07.09.2023)	US

(71) Applicant: **CHROMA MEDICINE, INC.** [US/US]; 201 Brookline Ave., Suite 1101, Boston, Massachusetts 02215 (US).

(72) Inventors: **JAFFE, Aron Brandon**; 201 Brookline Ave., Suite 1101, Boston, Massachusetts 02215 (US). **ABUBUCKER, Noorussahar**; 201 Brookline Ave., Suite 1101, Boston, Massachusetts 02215 (US). **ANGLERO-RODRIGUEZ, Yessenia**; 201 Brookline Ave.,

Suite 1101, Boston, Massachusetts 02215 (US). **MYER, Vic**; 201 Brookline Ave., Suite 1101, Boston, Massachusetts 02215 (US). **LOMBARDO, Angelo Leone**; 201 Brookline Ave., Suite 1101, Boston, Massachusetts 02215 (US). **CAPPELLUTI, Martino Alfredo**; 201 Brookline Ave., Suite 1101, Boston, Massachusetts 02215 (US).

(74) Agent: **CYNN, Esther** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

(54) Title: COMPOSITIONS AND METHODS FOR EPIGENETIC REGULATION OF HBV GENE EXPRESSION




FIGURE 14D

(57) Abstract: This invention relates to compositions, methods, strategies, and treatment modalities related to the epigenetic modification of hepatitis B virus (HBV) genes.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))